ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ADPT Adaptive Biotechnologies Corporation

3.90
-0.06 (-1.52%)
After Hours
Last Updated: 23:38:59
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adaptive Biotechnologies Corporation NASDAQ:ADPT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.06 -1.52% 3.90 3.90 3.92 4.11 3.86 4.07 1,451,187 23:38:59

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

21/11/2022 9:05pm

GlobeNewswire Inc.


Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Adaptive Biotechnologies Charts.

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Wednesday, November 30th at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive BiotechnologiesAdaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations201-396-1687Carrie Mendivil, Gilmartin Groupinvestors@adaptivebiotech.com

ADAPTIVE MEDIAMary Pat Lancelotta, Senior Vice President, Corporate Affairs & Communications646-382-4912media@adaptivebiotech.com

1 Year Adaptive Biotechnologies Chart

1 Year Adaptive Biotechnologies Chart

1 Month Adaptive Biotechnologies Chart

1 Month Adaptive Biotechnologies Chart

Your Recent History

Delayed Upgrade Clock